2026-01-02 - Analysis Report
Here's a comprehensive analysis of Natera Inc. (NTRA) based on the provided data:

**1) Return Rate Comparison**

*   **Company Overview:** Natera Inc. is a genetic testing company focused on non-invasive prenatal testing (NIPT) and cancer diagnostics.
*   **NTRA Cumulative Return:** 127.57%
*   **S&P 500 (VOO) Cumulative Return:** 91.40%
*   **Divergence:**
    *   **Current:** 22.5
    *   **Relative Divergence:** 46.6

    **Analysis:** NTRA has significantly outperformed the S&P 500 over the observed period. The current divergence suggests NTRA is performing better than the benchmark, however, the relative divergence indicates that the current divergence is not at its historical maximum, meaning there's room for further potential upside if it returns to the upper range of its past fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta     | Cap(B) |
|------------|----------|----------|----------|----------|--------|
| 2016-2018  | 16.0%    | 100.0%   | 13.0%    | 1.5      | 1.9    |
| 2017-2019  | 49.0%    | 99.8%   | 32.0%    | 1.7      | 4.7    |
| 2018-2020  | 177.0%   | 99.8%   | 156.0%   | 1.3      | 13.9   |
| 2019-2021  | 89.0%    | 99.6%   | 46.0%    | 1.4      | 13.0   |
| 2020-2022  | -74.0%   | 99.4%   | -72.0%   | 1.4      | 5.6    |
| 2021-2023  | -183.0%  | 93.9%   | -184.0%  | 1.6      | 8.7    |
| 2022-2024  | 11.0%    | 80.1%   | -9.0%    | 1.5      | 22.1   |
| 2023-2025  | 158.0%   | 57.5%   | 95.0%    | 1.3      | 31.9   |

**Analysis:**

*   **Alpha:** The Alpha values indicate Natera's performance relative to the market.  Positive Alpha means it outperformed its expected return based on its Beta, and negative Alpha means it underperformed.  The wide range (from -184% to 156%) demonstrates significant volatility in its performance.
*   **Beta:** The Beta consistently hovers around 1.3-1.7, suggesting that NTRA is more volatile than the overall market (S&P 500). It tends to amplify market movements.
*   **CAGR & MDD:** The CAGR (Compound Annual Growth Rate) shows large swings in annual returns, and the high MDD (Maximum Drawdown) values signify significant potential losses from peak to trough.
*   **Cap(B):** The Market Cap fluctuates significantly, reflecting the volatile nature of the stock.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** $229.09
*   **Previous Close:** $229.98
*   **Change:** -$0.39
*   **5-day SMA:** 231.93
*   **20-day SMA:** 233.21
*   **60-day SMA:** 211.50

**Analysis:** The stock price has experienced a slight dip recently (negative change). The 5-day and 20-day SMAs are above the current price, suggesting a short-term downward trend. The 60-day SMA is significantly lower, indicating that the overall longer-term trend is still upward but may be losing steam.

**3) Indicator Analysis**

*   **MRI (Market Risk Indicator):** 0.9 (High Investment Recommended)
*   **RSI (Relative Strength Index):** 42.73
*   **PPO (Percentage Price Oscillator):** -0.72
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Divergence Change (20 days):** -1.8 (Negative, indicating short-term decline)
*   **Expected Return (%):** -65.2% (Negative, indicating potential underperformance compared to S&P 500)

**Analysis:**

*   **MRI:** A high MRI suggests a favorable investment environment, according to this indicator.
*   **RSI:** An RSI of 42.73 is neutral, not indicating overbought or oversold conditions.
*   **PPO:** A negative PPO suggests a short-term bearish trend.
*   **Hybrid Signal:** The Hybrid signal suggests to buy, reinforcing the MRI recommendation with a very specific investment strategy.
*   **Divergence Change:** The recent decline in relative divergence aligns with the negative PPO and indicates short-term underperformance.
*   **Expected Return:** The very negative expected return is a significant red flag, suggesting potential long-term underperformance compared to the S&P 500.

**4) Recent News & Significant Events**

*   **Ninety One UK Ltd Sells Shares:** This could indicate a lack of confidence from a major institutional investor.
*   **Druckenmiller's Bet:** Billionaire Stanley Druckenmiller investing $1.2 Billion in These 3 Stocks is a positive sign.
*   **Publication of CALGB Study Findings:** The announcement of findings from the randomized, Phase III CALGB (Alliance)/SWOG 80702 Study is potentially positive news, but depends on the nature of the results.
*   **Medical Stock Hovers Near Buy Point:** This article indicates potential positive price movement.
*   **Analysts Bullish:** Analyst bullishness provides a positive outlook.
*   **Seeking Alpha 'Hold' Rating:** This suggests a neutral outlook, even with growth in MRD and margins.

**Analysis:** The news is mixed. While some headlines suggest positive momentum (analyst bullishness, potential buy points), others indicate potential concerns (institutional selling, neutral hold rating). The Druckenmiller investment is a significant positive factor.  The CALGB study publication could be a major catalyst, depending on the results.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Target Price (avg/high/low):** 246.26 / 285.00 / 186.00

**Analysis:** The analyst consensus is strongly positive, with a strong buy rating and an average target price significantly above the current price. This suggests that analysts, on average, believe the stock is undervalued. However, the wide range in target prices indicates some uncertainty.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-11-07 | -0.64 | 0.59 B$  |
| 2025-08-08 | -0.74 | 0.55 B$  |
| 2025-05-09 | -0.5  | 0.50 B$  |
| 2024-11-12 | -0.26 | 0.44 B$  |
| 2025-11-07 | -0.26 | 0.44 B$  |

**Analysis:** Natera is consistently reporting negative EPS (Earnings Per Share), though the most recent EPS is better than the prior two quarters.  Revenue is growing, which is a positive sign, but profitability remains a challenge. The revenue growth is critical to watch in coming quarters.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $0.59B   | 64.91%        |
| 2025-06-30   | $0.55B   | 63.41%        |
| 2025-03-31   | $0.50B   | 63.12%        |
| 2024-12-31   | $0.48B   | 62.94%        |
| 2024-09-30   | $0.44B   | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE     |
|--------------|----------|---------|
| 2025-09-30   | $1.25B   | -6.99%  |
| 2025-06-30   | $1.25B   | -8.10%  |
| 2025-03-31   | $1.24B   | -5.40%  |
| 2024-12-31   | $1.20B   | -4.50%  |
| 2024-09-30   | $0.88B   | -3.60%  |

**Analysis:**

*   **Revenue and Profit Margin:** Revenue is showing a strong upward trend, and the profit margin is consistently high (above 60%) and improving. This is very positive.
*   **Capital and Profitability:** Equity is relatively stable. However, the Return on Equity (ROE) is consistently negative, though it is improving somewhat.  This is a continuing cause for concern.

**7) Comprehensive Analysis**

Natera presents a mixed picture.

*   **Positives:** NTRA has outperformed the S&P 500 significantly historically, demonstrated by the substantial cumulative return and positive Alpha in several periods. Revenue is growing strongly, and gross profit margins are high and improving. Analysts have a strong buy consensus.  Druckenmiller's investment is a very strong signal. The MRI indicates a generally positive environment for investment.
*   **Negatives:** The stock is more volatile than the market (high Beta). NTRA is not currently profitable, as evidenced by negative EPS and ROE figures. The recent stock price action is slightly negative. The extremely negative expected return is a major concern, and indicates serious underperformance against the market.

**Overall Recommendation:**

The data presents a high-risk, high-reward scenario. The potential for significant growth is evident in the revenue and profit margin trends, as well as analyst sentiment. However, the lack of profitability, high volatility, and the extremely negative expected return should give investors pause.

**Recommendation:** Cautiously Optimistic. While the upside potential exists, it would be advisable to only invest a small portion of your portfolio. Also keep a close eye on upcoming news related to profitability.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.